Epoxide hydratase was solubilized from human liver microsomal fractions and purified to an extent where the specific activity was 40-fold greater than that of the liver homogenate. Combination of homogenate and purified preparation showed that the increase in activity was not due to the removal of an inhibitor. Monosubstituted oxiranes with a lipophilic substituent larger than an ethyl group (isopropyl, t-butyl, n-hexyl, phenyl) readily interacted as substrates or inhibitors with this purified human epoxide hydratase, whereas those with a small substituent (methyl, ethyl, vinyl) were inactive, probably reflecting greater affinity of the former epoxides owing to lipophilic binding sites near the active site of the enzyme. In a series of oxiranes having a lipophilic substituent of sufficient size (styrene oxides), monosubstituted as well as 1,1-and cis-1,2-disubstituted oxiranes readily served as substrates or inhibitors of the enzyme, but not the trans-1,2-disubstituted, tri-or tetra-substituted oxiranes. trans-Substitution at the oxirane ring apparently prevents access of the oxirane ring to the active site by steric hindrance. Epoxide hydratase was also solubilized from microsomal fractions of rat and guinea-pig liver and purified by the same procedure. Structural requirements for effective interaction of substrates, inhibitors and activators were qualitatively identical for epoxide hydratase from the three sources. However, several quantitative differences were observed. Thus human hepatic epoxide hydratase seems to be very similar to, although not identical with, the enzyme from guinea pig or rat. Studies with epoxide hydratase from the latter two species therefore appear to be significant with respect to man. In addition, knowledge of structural requirements for epoxides to serve as substrates for human epoxide hydratase may prove useful for drug design. Compounds which need aromatic or olefinic moieties for their desired effect would not be expected to lead to accumulation of epoxides if their structure was such as to allow for a metabolically produced epoxide to be rapidly consumed by epoxide hydratase.
Epoxide hydratase was solubilized from human liver microsomal fractions and purified to an extent where the specific activity was 40-fold greater than that of the liver homogenate. Combination of homogenate and purified preparation showed that the increase in activity was not due to the removal of an inhibitor. Monosubstituted oxiranes with a lipophilic substituent larger than an ethyl group (isopropyl, t-butyl, n-hexyl, phenyl) readily interacted as substrates or inhibitors with this purified human epoxide hydratase, whereas those with a small substituent (methyl, ethyl, vinyl) were inactive, probably reflecting greater affinity of the former epoxides owing to lipophilic binding sites near the active site of the enzyme. In a series of oxiranes having a lipophilic substituent of sufficient size (styrene oxides), monosubstituted as well as 1,1-and cis-1,2-disubstituted oxiranes readily served as substrates or inhibitors of the enzyme, but not the trans-1,2-disubstituted, tri-or tetra-substituted oxiranes. trans-Substitution at the oxirane ring apparently prevents access of the oxirane ring to the active site by steric hindrance. Epoxide hydratase was also solubilized from microsomal fractions of rat and guinea-pig liver and purified by the same procedure. Structural requirements for effective interaction of substrates, inhibitors and activators were qualitatively identical for epoxide hydratase from the three sources. However, several quantitative differences were observed. Thus human hepatic epoxide hydratase seems to be very similar to, although not identical with, the enzyme from guinea pig or rat. Studies with epoxide hydratase from the latter two species therefore appear to be significant with respect to man. In addition, knowledge of structural requirements for epoxides to serve as substrates for human epoxide hydratase may prove useful for drug design. Compounds which need aromatic or olefinic moieties for their desired effect would not be expected to lead to accumulation of epoxides if their structure was such as to allow for a metabolically produced epoxide to be rapidly consumed by epoxide hydratase.
Arene oxides and alkene oxides (formalistically resulting from the epoxidation of one of the double bonds of an aromatic nucleus or of an olefinic double bond respectively) are formed from aromatic and olefinic foreign compounds by liver microsomal mono-oxygenases (Jerina et al., 1968a (Jerina et al., , 1970 Leibman & Ortiz, 1970; Maynert et al., 1970; Selkirk et al., 1971; Grover et al., 1971a Grover et al., , 1972 . These epoxides are reactive electrophiles, and it has been clearly established that several of them bind to macromolecular tissue constituents (Grover & Sims, 1970; Lawley &Jarman, 1972) and exert mutagenic (Loveless, 1966; Huberman et al., 1971; Ames et al., 1972) and carcinogenic (Van Duuren et al., 1967a,b; Grover et al., 1971b; Marquardt et al., 1972) effects. Epoxide hydratase (EC 4.2.1.63) converts such epoxides into far less reactive vicinal diols (Oesch et al., 1971a,b ; for a complete review see Oesch, 1973) . To date no information about epoxide hydratase in man is available. Since these enzymes may be of critical importance to the extent of accumulation of reactive Vol. 139 epoxides and therefore to carcinogenic or hepatotoxic effects caused by such reactive metabolites of aromatic or olefinic compounds it was decided to investigate the existence and specificity of human epoxide hydratase. Epoxide hydratase was solubilized from human liver microsomal fractions and purified, and the specificity of the enzyme with respect to substrates, inhibitors and activators was investigated. By using the same procedure, epoxide hydratase was also solubilized and purified from rat and guinea-pig liver microsomal fractions and the specificity of the enzyme from these three sources was compared to clarify whether studies performed with epoxide hydratases from the latter two species are relevant to the situation in man.
Materials and Methods Chemicals
[7-3H]Styrene oxide (Oesch et al., 1971c) , [3,4,5,6-3H] cyclohexene oxide (Oesch et al., 1971b) , F. OESCH benzene oxide (Jerina et al., 1968b) and naphthalene 1,2-oxide (Vogel & Klarner, 1968) were synthesized as described. Other compounds were gifts or were prepared by standard procedures essentially as described for the synthesis of (3H]-styrene oxide (Oesch et al., 1971c) All epoxides gave a positive reaction with the epoxide spray reagent (Oesch et al., 1971c) . The reaction is based on the formation of alkali on heating an epoxide with Nal (Ross, 1950) , detected by a redox indicator. All compounds synthesized were checked by mass spectrometry (AEI MS 30 instrument). The parent peak, identified by its increasing intensity relative to other peaks at lowered energy of the bombarding electron beam to near the appearance potential (Silverstein & Bassler, 1968) , and fragmentations were compatible with the structures expected from the synthetic procedure for each compound prepared. Where enough synthetic material was available, n.m.r. data were also obtained. In (Oesch et al., 1971c) . Product formation was found to be linear with respect to time and protein concentration at each step in the purification. Protein concentrations were determined by the method of Lowry et al. (1951) with bovine serum albumin as a standard. The method of least squares was used to calculate regression lines for the determination of kinetic parameters, the Student's t test to establish the significance of differences between means (Snedecor & Cochran, 1967) . The measure of variation in this study is the S.E.M. Determinations were performed at least in triplicate.
Productformationfrom epoxides
Substrate (5,umol) was dissolved in 0.1 ml of acetonitrile and added dropwise, with swirling, to a mixture of 0.85 ml of 0.1 M-Tris-HCI buffer (pH 9.0) containing 0.2% (w/v) Tween 80 and 50j1 of the purified human epoxide hydratase at 0°C. After incubation at 37°C for 20min, products were extracted with 2 x 3 ml of ethyl acetate. The combined extract was dried over Na2SO4, concentrated under a stream of Ar at 40°C and chromatographed on thin-layer silica gel 60 F254 plates (E. Merck, Darmstadt, Germany) with benzene-chloroformethyl acetate (1:1:1, by vol.). Compounds were detected with u.v. light, and the product was extracted from the silica gel with 1.0ml of methanol and determined by u.v. spectroscopy [molar extinction coefficient, E, of trans-l1,2-dihydroxyindane 650 litremol-l-cmn1 at Ama. 265nm (Oesch et al., 1971b ); e for the glycol products from the styrene oxide derivatives were assumed to be similar to those of the corresponding oxides (214 and 225 litre molh' cm-' at A.. 258nm for 1-methyl-l-phenyloxirane and trans-2-methyl-1-phenyloxirane respectively), [3H]cyclohexene oxide was determined as described (Oesch et aL., 1971b, c) .
Solubilization and purification of a human hepatic epoxide hydratase A sample (80g) of human liver was obtained 10h after death from a healthy 43-year-old Caucasian woman. No gross lesions were observed on pathological examination. In rats post-mortem activity of epoxide hydratase (with [3H]styrene oxide as substrate) remained virtually unchanged for 16h after death (decrease less than 10% compared with fresh liver). This does not, of course, strictly exclude post-mortem changes in the human enzyme, since the body temperature decreases more rapidly in the rat than in the human.
All the steps in the following procedure were done at 0-5°C. The liver sample was homogenized in 200 ml ofO.25M-sucrose containing 0.01 M-sodium phosphate buffer (pH 7.4). The postmitochondrial supernatant (8500g, 15min) was centrifuged at lOOOOOg for 1 h and the resulting pellet was resuspended in lOOml of lOmm-sodium phosphate buffer (pH 7.4). A detergent (Cutscum; Fisher Scientific Co., Pittsburgh, Pa., U.S.A.) in aqueous solution was added dropwise, with gentle stirring, to give a final concentration of 1 % (w/v). The preparation was then centrifuged at lOOOOOg for 1 h and the upper layer, containing a whitish material, was removed by aspiration and the remainder of the supernatant was filtered through glass wool. (NH4)2SO4 was added to 10% saturation and the precipitated protein removed by centrifugation at 270OOg for 10 min. (NH4)2S04 was then added to the supernatant to 20% saturation. On centrifugation at 27000g for 20min some of the precipitate settled at the bottom of the tube, but most rose to the surface and was collected, dissolved in lOml of 10mM-sodium phosphate buffer (pH7.4) and desalted by Sephadex G-25 chromatography, the same buffer being used for elution. Active fractions were combined and frozen in solid C02-acetone. After storage for 12h at -70°C, the sample was thawed and the precipitated protein removed by centrifugation at 27000g for 20min. The supernatant (protein concentration 9.76mg/ml) was divided into lml portions, frozen in solid C02-acetone and stored at -70°C. This preparation lost less than 20% of its activity in 3 months. Purified epoxide hydratase preparations from the liver of male guinea pigs (300-400g, undetermined strain) and male Sprague-Dawley rats (200-250g) (protein concentrations of these purified preparations were 8.94 and 9.91 mg/ml respectively) were obtained by the same procedure.
Previous studies have shown that epoxide hydratase was localized exclusively in microsomal fractions of guinea-pig liver (Oesch et al., 1971c) . Microsomal fractions were therefore isolated from human liver, and epoxide hydratase was solubilized from the microsomal membranes by using Cutscum, a nonionic detergent. After precipitation and filtration steps (summarized in Table 1 ) an overall 40-fold increase in specific activity was achieved, with a recovery of 14% of the epoxide hydratase originally present in liver homogenate. Cutscum was added to a portion of the original homogenate (final concentration, 1 %, w/v) and this mixture was stirred for 5 min at 0°C. Combination of this suspension with the purified preparation in various proportions always resulted in an activity that was the sum of the activities in the two components (results not shown). Thus the increase in specific activity during purification is not likely to be due to the removal of an endogenous inhibitor. Moreover, epoxide hydratase activity was linear with respect to protein concentration at each step in the purification. Recovery of more than 100% of the epoxide hydratase activity present in the liver homogenate after Cutscum treatment (Table 1) possibly reflects exposure of active sites by the action of the detergent.
Epoxide hydratase was purified from guinea-pig and rat liver microsomal fractions by the same procedure. The ratio of the specific activity of the purified preparation to that of the homogenate was 39 for the guinea pig (107 versus 2.78 nmol of styrene glycol/min per mg of protein) and 32 for the rat enzyme (36.4 versus 1.14nmol of styrene glycol/min per mg of protein).
Hydration of [3H]styrene oxide by human epoxide hydratase was not inhibited by monosubstituted oxiranes if the substituent was a methyl, ethyl or vinyl group, indicating that these epoxides either do not bind to the active site of the enzyme or have a much lower affinity for this site than styrene oxide, since the concentration of all epoxides used was the same. However, the enzyme did interact with monosubstituted oxiranes if the substituent was an isopropyl, t-butyl, n-hexyl, phenyl or an even larger lipophilic group, presumably reflecting lipophilic binding sites near the active site of the enzyme (Table 2 ). In a series of oxiranes having such substituents (styrene oxides), human epoxide hydratase readily interacted with mono-, 1,1-and cis-1,2-disubstituted oxiranes, whereas trans-1,2-disubstituted oxiranes, tri-and tetra-substituted oxiranes did not inhibit the hydration of [3H]styrene oxide (Table 3 ). Table 4 shows that the potency of five styrene oxides as inhibitors was paralleled by their ability to serve as substrate for purified human epoxide hydratase: styrene oxide and 1-methyl-I-phenyloxirane were good inhibitors and also good substrates, whereas trans-2-methyl-1-phenyloxirane, 2,2-dimethyl-1-phenyloxirane and 1,2,2-trimethyl-1-phenyloxirane did not serve as either inhibitors or substrates. The topography around the active site of the enzyme appears to be such that a trans-1,2-disubstitution at the oxirane ring sterically prevents the access of the oxirane ring to the active site, even if the substituent at the 2-position is as small as a methyl group. With 1,1-disubstituted oxiranes effective interaction with the enzyme appeared to decrease with increasing bulk of the two substituents (Table 3) . Results obtained with purified epoxide hydratase from human, guinea-pig and rat liver appeared qualitatively identical (Tables 2 and 3 ). On the other hand, several quantitative differences became apparent. Thus n-octene 1,2-oxide was a stronger inhibitor of epoxide hydratase from rat, 3-phenylpropene 1,2-oxide of the enzyme from man and cis-2-methyl-1-phenyloxirane of the enzyme from guinea pig and rat compared with the enzyme from the other species, suggesting that the epoxide hydratases purified from man, guinea-pig and rat liver are very similar, but not completely identical. Table 5 shows that the ability of several styrene oxides with different substituents on the aromatic In a more extensive study on structure-activity relationships in a purified preparation from guinea-pig liver (Oesch & Daly, 1971) , no correlations between the electronic effects of Vol. 139 substituents and the potency of the unsubstituted styrene oxides as inhibitors were apparent (Oesch et al., 1971a) . The most potent inhibitor of the epoxide hydratase purified from human liver was 3,3,3-trichloropropene oxide ( inhibition was almost complete. Both the bulk and the strong electron-withdrawing effect of the trichloromethyl group appeared essential, since 3,3,3-trifluoropropene oxide and 3,3,3-trimethylpropene oxide (3,3-dimethylbutene oxide) were much weaker inhibitors. Again hepatic epoxide hydratase preparations from man, guinea pig and rat acted similarly, with some quantitative differences especially with respect to the inhibitory effect of the 3,3,3-trifluoropropene oxide in the three preparations. Oxiranes fused to rings also appeared to interact with epoxide hydratase from the three sources to a generally similar extent (Table 7) . Indene oxide proved to be both a good inhibitor (Table 7) and an excellent substrate (Table 4) for human epoxide hydratase. Cyclohexene oxide, on the other hand, had been previously shown to be a good inhibitor, but a very poor substrate for guinea-pig hepatic epoxide hydratase, and kinetic analysis showed the inhibition to be ofthe non-competitive type (Oesch et al., 1971a) . Cyclohexene oxide was also a poor substrate for the enzyme from human liver (Table 4) , but was much less potent an inhibitor than for guinea-pig epoxide hydratase (Table 7) . Inhibition of epoxide hydratase from human liver by cyclohexene oxide might therefore be expected to be of the mixed type. However, kinetic analysis showed the inhibition of the human enzyme to be non-competitive (Fig. 1) . 2.6 * * Radioactive substrate was used. Product was isolated and determined as described (Oesch et al., 1971b,c (Jerina et al., 1968a (Jerina et al., , 1970 Leibman & Ortiz, 1970; Maynert et al., 1970; Selkirk et al., 1971; Grover et al., 1971a Grover et al., , 1972 may produce disturbance of normal cell functions (Loveless, 1966; Van Duuren et al., 1967a,b; Huberman et al., 1971; Grover et al., 1971b; Ames et al., 1972; Marquardt et al., 1972) owing to their alkylating ability (Grover & Sims, 1970; Lawley & Jarman, 1972) , and since epoxide hydratase transforms such epoxides to much less reactive diols (Oesch et al., 1971a,b; Oesch, 1973 , and references therein), activators of human epoxide hydratase appear to be of special interest. Such activators could serve as tools to provide insight into the mechanism of carcinogenesis, mutagenesis and cytotoxicity produced by aromatic or olefinic compounds, and may even be useful in alleviating or preventing these effects. This action would be even more pronounced if the compound was at the same time an inhibitor 1974 Table 8 shows that some mono-oxygenase inhibitors, namely two imidazoles (Johnson et al., 1969; Leibman, 1971) and metyrapone (2-methyl-1,2-di-(3-pyridyl)propan-1-one) (Netter et al., 1967; Leibman, 1969) were activators of human hepatic epoxide hydratase in vitro. Aminogluthetimide (3-(p-aminophenyl)-3-ethyl-2,6-dioxopiperidine) which, with respect to mono-oxygenases, has several properties in common with metyrapone (Dexter et al., 1967) , had no effect on epoxide hydratase. Ethanol, which has been reported to induce mono-oxygenases (Lieber & Vol. 139 De Carli, 1971) , at high concentrations (2.7M) enhanced the activity of human epoxide hydratase in vitro, whereas acetone, which stimulates activity of mono-oxygenases in vitro (Anders, 1968; Daly et al., 1969; Daly, 1970; Vainio & Hiinninen, 1972) had no effect on epoxide hydratase. Changes of activity of epoxide hydratase in vitro produced by these compounds are qualitatively very similar with respect to epoxide hydratase purified from the liver of man, guinea pig or rat. Quantitatively, the most striking difference was a considerably weaker effect of 1-(2-isopropylphenyl)-imidazole on the rat liver enzyme as compared with the preparations from guinea pig and man ( In conclusion, the epoxide hydratase purified from human liver microsomal fraction appeared to be qualitatively identical with the enzyme from rat and guinea pig with respect to specificity towards substrates, inhibitors and activators. Epoxides with various substitution patterns around the oxirane ring, monosubstituted oxiranes with various sizes of substituents, styrene oxides with different substituents on the aromatic ring, propene oxides with substituents of different bulk and electronegativity in the 3-position, and oxiranes fused to rings, displayed the full range of0-100 % inhibition towards hydration of [3H]styrene oxide by human epoxide hydratase.
Epoxide hydratase from guinea pig or rat proved qualitatively sensitive and insensitive to the same compounds respectively. The same was true for several activators. However, some quantitative differences were noted, the most striking being the action of cyclohexene oxide on epoxide hydratase from human as compared with guinea-pig liver. With both preparations this compound was a very poor substrate, but its inhibitory activity was potent with hepatic epoxide hydratase from guinea pig but much weaker with the hepatic enzyme from man. However, kinetic analysis showed the inhibition to be purely non-competitive in both preparations, indicating basically similar mechanisms even in those cases where quantitative differences were observed.
It therefore appears that human epoxide hydratase is probably very similar to, although not identical with, the guinea-pig and rat enzyme, and that studies on epoxide hydratase from the latter species are important with respect to the human enzyme. The structural features required for an epoxide to interact with the human epoxide hydratase as delineated in Tables 2-6 F. OESCH especially in view of the fact that both enzyme systems, mono-oxygenases responsible for the formation of epoxides and epoxide hydratases, are localized in the membrane of the endoplasmic reticulum, and moreover appear to be architecturally and functionally closely coupled . These delineations may therefore prove useful for the design of drugs which require an aromatic or olefinic moiety for their intended pharmacological effect.
